The FDA approved Wilserdly, or giredestrant, with everolimus for eligible adults with ESR1-mutated advanced breast cancer after a trial nearly doubled progression-free survival.
Wilserdly Pill Nearly Doubled Time Without Progression in ESR1-Mutated Advanced Breast Cancer, Winning FDA Approval With Everolimus
by | Nov 17, 2026 | Uncategorized | 0 comments

Recent Comments